Detalhe da pesquisa
1.
Imetelstat in patients with lower-risk myelodysplastic syndromes who have relapsed or are refractory to erythropoiesis-stimulating agents (IMerge): a multinational, randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet
; 403(10423): 249-260, 2024 Jan 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-38048786
2.
Tracking the evolution of therapy-related myeloid neoplasms using chemotherapy signatures.
Blood
; 141(19): 2359-2371, 2023 05 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-36626250
3.
An 8-year pragmatic observation evaluation of the benefits of allogeneic HCT in older and medically infirm patients with AML.
Blood
; 141(3): 295-308, 2023 01 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-36260765
4.
Consensus proposal for revised International Working Group 2023 response criteria for higher-risk myelodysplastic syndromes.
Blood
; 141(17): 2047-2061, 2023 04 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-36724453
5.
Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet
; 401(10388): 1571-1583, 2023 05 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-37116523
6.
Patterns of Diagnostic Evaluation and Determinants of Treatment in Older Patients With Non-transfusion Dependent Myelodysplastic Syndromes.
Oncologist
; 28(10): 901-910, 2023 10 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-37120291
7.
Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes.
N Engl J Med
; 382(2): 140-151, 2020 01 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-31914241
8.
Machine learning integrates genomic signatures for subclassification beyond primary and secondary acute myeloid leukemia.
Blood
; 138(19): 1885-1895, 2021 11 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34075412
9.
Multisite 11-year experience of less-intensive vs intensive therapies in acute myeloid leukemia.
Blood
; 138(5): 387-400, 2021 08 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-34351368
10.
STIMULUS-MDS2 design and rationale: a phase III trial with the anti-TIM-3 sabatolimab (MBG453) + azacitidine in higher risk MDS and CMML-2.
Future Oncol
; 19(9): 631-642, 2023 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-37083373
11.
Machine learning demonstrates that somatic mutations imprint invariant morphologic features in myelodysplastic syndromes.
Blood
; 136(20): 2249-2262, 2020 11 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-32961553
12.
SF3B1-mutant MDS as a distinct disease subtype: a proposal from the International Working Group for the Prognosis of MDS.
Blood
; 136(2): 157-170, 2020 07 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-32347921
13.
A phase 1b study of glasdegib + azacitidine in patients with untreated acute myeloid leukemia and higher-risk myelodysplastic syndromes.
Ann Hematol
; 101(8): 1689-1701, 2022 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-35488900
14.
Diagnosis and Treatment of Myelodysplastic Syndromes: A Review.
JAMA
; 328(9): 872-880, 2022 09 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-36066514
15.
Results of a randomized phase 3 study of oral sapacitabine in elderly patients with newly diagnosed acute myeloid leukemia (SEAMLESS).
Cancer
; 127(23): 4421-4431, 2021 12 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34424530
16.
Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML.
N Engl J Med
; 378(25): 2386-2398, 2018 Jun 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-29860938
17.
Frequency and perturbations of various peripheral blood cell populations before and after eculizumab treatment in paroxysmal nocturnal hemoglobinuria.
Blood Cells Mol Dis
; 87: 102528, 2021 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-33341510
18.
Proposals for revised IWG 2018 hematological response criteria in patients with MDS included in clinical trials.
Blood
; 133(10): 1020-1030, 2019 03 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-30404811
19.
Molecular remission and response patterns in patients with mutant-IDH2 acute myeloid leukemia treated with enasidenib.
Blood
; 133(7): 676-687, 2019 02 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-30510081
20.
Clinical benefit of glasdegib plus low-dose cytarabine in patients with de novo and secondary acute myeloid leukemia: long-term analysis of a phase II randomized trial.
Ann Hematol
; 100(5): 1181-1194, 2021 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-33740113